METROPOLIS - Metropolis Healt
📢 Recent Corporate Announcements
Metropolis Healthcare Limited has scheduled an interaction with institutional investors and analysts for March 23, 2026. The company will participate in the DAM Capital Investor Conference, involving both one-on-one and group meetings starting from 10:00 a.m. IST. Management has clarified that discussions will be based strictly on publicly available information, with no unpublished price-sensitive information being shared. This is a standard investor relations activity aimed at maintaining transparency with the market.
- Investor meeting scheduled for March 23, 2026, at 10:00 a.m. IST
- Participation in the DAM Capital Investor Conference
- Format includes both One-to-One and Group Meeting interactions
- Compliance with SEBI Regulation 30(6) for disclosure of investor schedules
Metropolis Healthcare Limited has finalized March 20, 2026, as the record date for its 3:1 bonus share issuance. Shareholders holding the stock on this date will be eligible to receive three additional fully paid-up equity shares for every one share they currently own. This corporate action follows the board's recommendation in February 2026 and recent shareholder approval. The deemed date for the allotment of these new shares is scheduled for March 23, 2026.
- Bonus issue ratio confirmed at 3:1 (3 new shares for every 1 existing share)
- Record date for eligibility fixed as Friday, March 20, 2026
- Deemed date of allotment for bonus shares is Monday, March 23, 2026
- Face value of shares remains unchanged at INR 2 per equity share
Metropolis Healthcare Limited has announced its participation in the Investec Investor Conference scheduled for March 10, 2026. The engagement will involve both one-to-one and group meetings with institutional investors and analysts starting from 10:00 a.m. IST. The company has explicitly stated that discussions will be limited to publicly available information, with no unpublished price-sensitive information being shared. Such meetings are standard practice for mid-to-large cap companies to maintain transparency and manage investor relations.
- Meeting scheduled for March 10, 2026, at the Investec Investor Conference.
- Interaction format includes both One-to-One and Group Meeting sessions.
- Discussions will strictly adhere to publicly available information to avoid UPSI disclosure.
- The intimation is filed under Regulation 30(6) of the SEBI Listing Regulations, 2015.
Metropolis Healthcare reported a strong 26% year-on-year group revenue growth for Q3 FY26, with organic revenue increasing by 15%. A significant highlight is the Board's approval of a 3:1 bonus issue, aimed at rewarding shareholders and improving stock liquidity. Management maintained its FY26 organic growth guidance of 12-13% and expects margin expansion driven by the in-housing of high-margin genomics tests. The company is also seeing positive results from its strategic shift toward high-quality B2B and institutional partnerships.
- Group revenue increased by 26% YoY in Q3 FY26, while organic revenue grew by 15% YoY.
- Board approved a 3:1 bonus issue (3 fully paid-up shares for every 1 existing share).
- Organic patient volumes grew by 9% YoY, supported by a 15% growth in the B2C segment.
- Core Diagnostics is expected to achieve high single-digit EBITDA margins in Q4 FY26 following the launch of in-house genomics testing.
- Maintained FY26 organic revenue growth guidance of 12-13% with an outlook for expanded margins.
Metropolis Healthcare has initiated a postal ballot process to seek shareholder approval for a 3:1 bonus share issue. Under this proposal, shareholders will receive three new fully paid-up equity shares of ₹2 each for every one existing share held. The company intends to capitalize a sum not exceeding ₹31.10 crore from its securities premium, general reserves, or retained earnings. The e-voting period for this resolution is scheduled from February 7, 2026, to March 8, 2026, with final results expected by March 10, 2026.
- Proposed bonus issue in the ratio of 3:1 (3 new shares for every 1 existing share)
- Total capitalization amount from reserves not to exceed ₹31.10 crore
- Remote e-voting period set for February 7, 2026, to March 8, 2026
- Record date for eligibility to be determined and announced following shareholder approval
- Bonus shares will rank pari-passu in all respects with existing equity shares
Metropolis Healthcare has officially released the audio recording of its earnings conference call for the third quarter and nine months ended December 31, 2025. The call, held on February 05, 2026, provided management's perspective on the company's financial performance and operational strategy. This disclosure is a standard regulatory requirement under SEBI LODR Regulations to ensure transparency for all shareholders. Investors can access the recording via the link provided on the company's investor relations website.
- Audio recording of Q3 FY26 earnings call made available on February 05, 2026.
- The call discussed financial results for the quarter and nine-month period ending December 31, 2025.
- Disclosure made in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- Recording provides insights into management commentary following the results announcement.
Metropolis Healthcare Limited has announced a series of interactions with institutional investors and analysts scheduled for mid-February 2026. The first set of meetings, hosted by Axis Capital, will take place on February 12, 2026, starting at 10:00 a.m. IST. A second round of interactions organized by Spark Institutional Equities is set for February 16, 2026, beginning at 11:00 a.m. IST. These sessions will include both one-on-one and group formats to discuss publicly available information.
- Interaction with Axis Capital scheduled for February 12, 2026, from 10:00 a.m. IST onwards
- Interaction with Spark Institutional Equities scheduled for February 16, 2026, from 11:00 a.m. IST onwards
- Meetings will consist of both One-to-One and Group interaction formats
- Company confirms no unpublished price sensitive information (UPSI) will be discussed
- Disclosure made under Regulation 30(6) of SEBI Listing Regulations
Metropolis Healthcare reported a strong Q3FY26 with organic revenue growing 15% YoY to ₹371 Cr and Group revenue (including recent acquisitions) rising 26% to ₹406 Cr. Organic EBITDA margins expanded significantly by 280 bps to 25.0%, driven by operating leverage and productivity gains. The company witnessed robust volume growth with organic patient counts up 9% and test volumes up 8%. Strategic focus on high-value segments like TruHealth (wellness) and Specialty testing, which grew 25% and 16% respectively, continues to drive premiumization and higher realizations.
- Organic PAT surged 52% YoY to ₹48 Cr, while Group PAT grew 63% to ₹51 Cr
- Organic EBITDA margin improved to 25.0%, up from 22.2% in the previous year
- TruHealth (wellness) segment revenue grew 25% YoY, now contributing 19% of total revenue
- Revenue Per Patient (RPP) increased by 6% YoY to ₹1,116, reflecting a shift toward premium tests
- Network expanded to 219 labs and over 4,800 service points across approximately 750 towns
Metropolis Healthcare reported a strong performance for Q3FY26, with revenue growing 26% YoY to ₹406 crore. Profit After Tax (PAT) surged 63% YoY to ₹51 crore (excluding exceptional items), while EBITDA grew 32% to ₹95 crore. The growth was driven by a 14% increase in patient volumes and a significant 35% jump in B2B revenues. Additionally, the Board has approved a 3:1 bonus issue, reflecting management's confidence in the company's long-term growth trajectory.
- Revenue increased by 26% YoY to ₹406 crore, supported by a 14% growth in patient volumes.
- PAT (excluding exceptional items) grew 63% YoY to ₹51 crore, while EBITDA rose 32% to ₹95 crore.
- B2B segment outperformed with ~35% YoY growth, while TruHealth and Specialty portfolios grew 37% and 34% respectively.
- Operational metrics improved with Revenue per Test (RPT) up 11% and Revenue per Patient (RPP) up 10% YoY.
- The Board approved a 3:1 bonus issue of equity shares to reward shareholders.
Metropolis Healthcare has approved a significant 3:1 bonus issue, providing three new equity shares for every one share held by investors. For the quarter ended December 31, 2025, the company reported standalone revenue of ₹334.78 crore and a profit of ₹32.03 crore, showing growth over the previous year's ₹27.40 crore profit. The company is also streamlining operations by transferring its EQAS division to a wholly-owned subsidiary for ₹1.25 crore via a slump sale. Results were slightly impacted by a one-time exceptional charge of ₹7.96 crore related to the new Labour Code provisions.
- Approved a 3:1 bonus issue of equity shares of face value ₹2 each.
- Standalone revenue from operations grew to ₹334.78 crore in Q3 FY26 from ₹296.88 crore in Q3 FY25.
- Standalone PAT for the quarter stood at ₹32.03 crore, up 16.9% compared to ₹27.40 crore YoY.
- Divested EQAS Division to a wholly-owned subsidiary for ₹1.25 crore to optimize business structure.
- Recognized a non-recurring exceptional expense of ₹7.96 crore due to the implementation of new Labour Codes.
Metropolis Healthcare has recommended a massive 3:1 bonus issue, granting 3 new shares for every 1 held, subject to shareholder approval. For Q3 FY26, the company reported a standalone revenue of ₹334.78 crore, representing a 12.8% YoY growth, though performance was lower compared to the previous quarter. Net profit for the quarter stood at ₹32.03 crore, which was impacted by a one-time exceptional charge of ₹7.96 crore related to the implementation of new Labour Codes. Additionally, the board approved the slump sale of its EQAS business division to a wholly-owned subsidiary for ₹1.25 crore to streamline operations.
- Approved 3:1 bonus issue (3 equity shares for every 1 held) to increase liquidity.
- Standalone Revenue from operations grew 12.8% YoY to ₹334.78 crore.
- Net Profit stood at ₹32.03 crore, up 16.9% YoY but down 31.3% sequentially from Q2 FY26.
- Recognized a non-recurring exceptional expense of ₹795.67 lakhs due to new Labour Code regulations.
- Approved slump sale of the EQAS Division to a subsidiary for a consideration of ₹1.25 crore.
Metropolis Healthcare reported a steady performance for Q3 FY26 with standalone revenue growing 12.7% YoY to ₹334.78 crore. Net profit for the quarter rose 16.9% YoY to ₹32.03 crore, even after accounting for a ₹7.96 crore exceptional item related to new Labour Code provisions. A significant highlight for shareholders is the recommendation of a 3:1 bonus issue, which will quadruple the share count. The company also announced an internal restructuring, moving its EQAS business to a wholly-owned subsidiary for ₹1.25 crore.
- Standalone Revenue from operations increased 12.7% YoY to ₹334.78 crore in Q3 FY26.
- Net Profit grew 16.9% YoY to ₹32.03 crore, despite a sequential decline from Q2 FY26.
- Board recommended a 3:1 bonus issue (3 new shares for every 1 existing share held).
- Recognized an exceptional expense of ₹795.67 lakhs due to the impact of new Government Labour Codes.
- 9M FY26 revenue crossed the ₹1,000 crore mark, reaching ₹1,014.13 crore compared to ₹904.59 crore YoY.
Metropolis Healthcare Limited has announced its Q3FY26 earnings conference call, scheduled for February 5, 2026, at 9:00 AM IST. The call, organized by ICICI Securities, will focus on the financial results for the quarter ended December 31, 2025. Senior management, including the Chairperson, Managing Director, and CFO, will be available to address queries regarding company performance. This routine disclosure allows investors to prepare for the upcoming financial performance review and management commentary.
- Earnings call scheduled for February 5, 2026, at 09:00 a.m. IST.
- Discussion will cover financial performance for the quarter ended December 31, 2025.
- Call hosted by ICICI Securities with participation from top management including Chairperson Ms. Ameera Shah.
- Universal access numbers provided: +91 22 6280 1144 and +91 22 7115 8045.
Metropolis Healthcare Limited has approved the allotment of 9,960 equity shares to employees under its Restrictive Stock Unit (RSU) Plan, 2020. The shares were issued at an exercise price of INR 2 per share, resulting in a total aggregate value of INR 19,920. This allotment has increased the company's total issued share capital to INR 10,36,63,884, comprising 5,18,31,942 equity shares. Investors should note that 50% of these newly allotted shares are subject to a one-year lock-in period ending January 13, 2027.
- Allotment of 9,960 equity shares at an exercise price of INR 2 per share
- Total issued share capital increased to 5,18,31,942 shares post-allotment
- 50% of the allotted shares are subject to a 1-year lock-in period until January 13, 2027
- Total paid-up share capital now stands at INR 10.36 crore
Metropolis Healthcare has launched its 'Centre of Genomics' to scale precision diagnostics and genomic research in India. The facility is equipped with Illumina’s NovaSeq™ X Series, which can generate over 20,000 whole genomes annually, doubling the throughput of previous systems. Currently offering 220+ validated genomic tests, the company plans to expand this portfolio to over 500 assays within the next two to three years. This strategic move targets high-margin segments like oncology, neurology, and rare diseases while positioning the company for global clinical trial partnerships.
- Launched Centre of Genomics supported by two CAP-accredited labs in Mumbai and Delhi NCR.
- Deployed Illumina’s NovaSeq™ X Series technology capable of 20,000+ whole genomes per year.
- Current portfolio of 220+ genomic tests to be expanded to 500+ assays in the next 2-3 years.
- Focuses on high-impact clinical areas including oncology, reproductive health, and transplant immunology.
- Positioning as a strategic partner for global pharmaceutical programs and companion diagnostics.
Financial Performance
Revenue Growth by Segment
Metropolis delivered a broad-based revenue growth of 23% YoY in Q2 FY26. Volume growth is projected to remain in the double-digit range of 10% to 11% for the remainder of the fiscal year. The wellness and specialized testing segments are key drivers, commanding higher realizations compared to routine tests.
Geographic Revenue Split
The company is focusing on its 'Top 800 towns' via a Micro Market Strategy and 'T3 Acceleration' to reduce geographic concentration. While specific regional percentages are not disclosed, CRISIL identifies the reduction of geographic concentration as a key upward rating sensitivity factor.
Profitability Margins
Operating margins improved to 25.0% in Q1 FY25 from 23.0% in Q1 FY24. Q2 FY26 margins stood at 24.3%, benefiting from high-volume seasonality. The company aims to sustain margins at 25-26% over the medium term, though the Core Diagnostics acquisition currently dilutes margins by 100-130 bps.
EBITDA Margin
The operating margin for FY25 was 24.2%. The acquisition of Core Diagnostics, which initially operated at single-digit margins, is expected to reach double-digit margins by the end of Year 1 and align with Metropolis's 23-24% levels by FY28 (Year 3 of acquisition).
Capital Expenditure
Planned annual capital expenditure, including Right-of-Use (ROU) asset additions, is estimated at INR 130-140 Cr over the near-to-medium term to support laboratory footprint expansion.
Credit Rating & Borrowing
CRISIL reaffirmed the long-term rating at 'CRISIL AA-' but revised the outlook to 'Stable' from 'Positive'. The short-term rating is 'CRISIL A1+'. The company was debt-free as of March 31, 2024, maintaining a robust financial risk profile.
Operational Drivers
Raw Materials
Diagnostic reagents, chemicals, and laboratory consumables (referred to as 'input materials' in documentation).
Capacity Expansion
Metropolis is expanding its laboratory footprint and customer touchpoints to drive volume-led growth. It utilizes a hub-and-spoke model to service customers efficiently across its widespread network.
Raw Material Costs
Not disclosed as a specific percentage of revenue, but the company is redefining its cost structure and implementing automation to mitigate pricing pressure from competitors.
Manufacturing Efficiency
Efficiency is driven by automation, digitization, and an in-house R&D setup for continuous process improvement. High-volume quarters (like Q2) significantly improve operating leverage.
Logistics & Distribution
Distribution is managed through a hub-and-spoke model; costs are being optimized through technology and process integration following recent acquisitions.
Strategic Growth
Expected Growth Rate
23%
Growth Strategy
Growth is pursued through the 'Metropolis 3.0' strategy: strengthening the core in 800 towns, expanding into adjacencies like Radiology and Genomics, and executing bolt-on acquisitions like Core Diagnostics. The company is also cleaning up acquired businesses in Year 1 to set a foundation for faster growth in Year 2.
Products & Services
Acute illness diagnostics, specialized testing, wellness packages, clinical trial turnkey projects for pharma companies, genomics, and primary healthcare services.
Brand Portfolio
Metropolis Healthcare, Core Diagnostics, Dr. Sushil Shah’s Pathology Laboratory.
New Products/Services
Expansion into high-science domains such as Genomics and complementary radiology services is expected to drive future revenue contribution.
Market Expansion
Focusing on 'T3 Acceleration' and 'Micro Market' strategies to deepen penetration in the Top 800 Indian towns.
Market Share & Ranking
Metropolis is a leading organized player in the Indian diagnostic industry, benefiting from a natural market consolidation where unorganized labs are struggling with compliance.
Strategic Alliances
The company engages in turnkey projects with pharmaceutical companies for clinical trials, which currently represent a small but high-margin segment.
External Factors
Industry Trends
The industry is seeing a shift from unorganized to organized players (current growth 23% for MHL) due to rising technology and quality requirements. Consolidation is accelerating as smaller labs find it difficult to sustain compliance.
Competitive Landscape
Competition includes large conglomerates, hospital networks, pharmaceutical companies, health-tech platforms, and agile startups.
Competitive Moat
Moat consists of established brand equity, clinician trust, and a widespread hub-and-spoke network. Sustainability is supported by high entry barriers in specialized testing and 'high-science' domains like Genomics.
Macro Economic Sensitivity
Operations are sensitive to Indian demand conditions and the availability of input materials. Economic slowdowns could impact discretionary wellness spending.
Consumer Behavior
Increasing consumer preference for wellness and preventive testing, which commands higher realizations and supports margin expansion.
Geopolitical Risks
Socio-political disruptions like riots or strikes are identified as business continuity risks that could impact logistics and service delivery.
Regulatory & Governance
Industry Regulations
Operations must comply with NABL/CAP accreditations and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Rising compliance and quality standards are driving industry consolidation.
Environmental Compliance
The company is embedding ESG principles across its value chain to enhance stakeholder confidence and access to capital markets.
Risk Analysis
Key Uncertainties
Integration risks of Core Diagnostics could lead to slower-than-anticipated margin improvement. Large debt-funded acquisitions (if any) could weaken debt metrics.
Geographic Concentration Risk
Historically high concentration in certain regions; CRISIL monitors the reduction in geographic concentration as a key rating factor.
Third Party Dependencies
Dependency on technology partners and logistics vendors for business continuity.
Technology Obsolescence Risk
Rapidly evolving technology could disrupt traditional diagnostic models; Metropolis mitigates this by investing in automation and digital transformation.
Credit & Counterparty Risk
Receivables are well-managed at under 40 days, indicating high-quality credit exposure.